ArticleCureus2025
Prevalence of Serotonergic Drug Use in Patients Exposed to Perioperative Methylene Blue: A Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethylene blue is a widely used medication in various medical procedures, particularly in cardiovascular operations where it serves as a diagnostic dye and a treatment for conditions like methemoglobinemia and vasoplegic syndrome. While its clinical applications are well-documented, methylene blue's pharmacological properties as a monoamine oxidase (MAO) inhibitor present a potential risk of serotonin syndrome when administered to patients taking serotonergic medications. This study examines the prevalence of serotonergic medications, including lithium, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs), in patients who were administered methylene blue.
methodsThis cross-sectional study used de-identified electronic health records (EHRs) from the TriNetX database, which pools data from 97 healthcare organizations. The analysis focused on isolating patients who were administered methylene blue perioperatively and calculating the prevalence of concomitant serotonergic drug use by drug class.
resultsThe large database analysis revealed that among the 249,131 patients who received perioperative methylene blue, 25,282 (10.14%) were concomitantly given serotonergic drugs. By drug class, SSRIs had the highest concomitant use with 15,705 cases and a prevalence of 63.04/1000 cases. Next were SNRIs, with 6,341 cases and a prevalence of 25.45/1000 cases; TCAs, with 2,979 cases and a prevalence of 11.96/1000 cases; lithium, with 292 cases and a prevalence of 1.17/1000 cases; and MAO inhibitors, which had the lowest concomitant use at 65 cases and a prevalence of 0.26/1000 cases.
conclusionThe prevalence of serotonergic agent use in patients administered methylene blue is relatively high exceeding 10%, with the highest prevalence observed in those on SSRIs, followed by SNRIs and TCAs. This underscores the importance of a thorough preoperative evaluation by an anesthesiologist to minimize the risk of intraoperative complications such as serotonin syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.